We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

September 16, 2016

United States of America et al v. Janssen Pharmaceutical N.V. et al

Track this case

Case Number:

2:16-cv-06997

Court:

California Central

Nature of Suit:

Qui Tam (31 U.S.C. § 3729(a))

Judge:

R. Gary Klausner

Firms

Companies

Sectors & Industries:

View recent docket activity


Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.


Coverage

  1. April 20, 2018

    Janssen Escapes Whistleblower Suit Over Off-Label Opioids

    A California federal judge Thursday nixed a False Claims Act suit accusing Johnson & Johnson subsidiary Janssen Pharmaceutical NV of using unlawful marketing practices to boost off-label sales of its opioid prescription drugs, saying a change of the pseudonym for the whistleblower who filed the suit violated the FCA’s first-to-file doctrine.

1 other articles on this case. View all »

Parties

To view the parties, register now.